Metastatic Breast Cancer - Pipeline Review, H2 2014

Metastatic Breast Cancer - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Metastatic Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned
AbbVie Inc. Advaxis, Inc. Advenchen Laboratories, LLC AlphaMab Co., Ltd AlphaVax, Inc. Amarna Therapeutics B.V. Amgen Inc. AngioGenex, Inc. Aphios Corporation Array BioPharma Inc. AstraZeneca PLC AVEO Pharmaceuticals, Inc. Bavarian Nordic A/S Bayer AG BIOCAD Biocon Limited BioMarin Pharmaceutical Inc. BioNumerik Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CASI Pharmaceuticals Inc. Celgene Corporation Celldex Therapeutics, Inc. Celltrion, Inc. Corcept Therapeutics Incorporated CTI BioPharma Corp. Curadis GmbH Daiichi Sankyo Company, Limited Dompe Farmaceutici S.p.A. Eisai Co., Ltd. Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Etubics Corporation F. Hoffmann-La Roche Ltd. Galileo Research s.r.l. Genentech, Inc. Genor BioPharma Co., Ltd. GlaxoSmithKline plc Glycotope GmbH GTx, Inc. Hospira, Inc. Immune Design Corp. Immunomedics, Inc. Immunovative Therapies, Ltd. Immutep S.A. Imugene Limited Inbiopro Solutions Pvt. Ltd. Incyte Corporation Jiangsu Hengrui Medicine Co., Ltd. Johnson & Johnson Kadmon Corporation, LLC Kancera AB Laboratoires Pierre Fabre SA Mabion SA MacroGenics, Inc. MedImmune, LLC Merck & Co., Inc. Merrimack Pharmaceuticals, Inc. Merus B.V. MetaStat, Inc. Millennium Pharmaceuticals, Inc. Morphotek, Inc. NanoCarrier Co., Ltd. Natco Pharma Limited Nektar Therapeutics Neopharm Ltd. NewLink Genetics Corporation Nippon Kayaku Co., Ltd. Northwest Biotherapeutics, Inc. Novartis AG Oasmia Pharmaceutical AB OBI Pharma, Inc. Oncolytics Biotech Inc. OncoMed Pharmaceuticals, Inc. Paras Biopharmaceuticals Finland Oy Peregrine Pharmaceuticals, Inc. Pfizer Inc. Pharma Mar, S.A. Plexxikon Inc. Polaris Group Polyphor Ltd. Puma Biotechnology, Inc. Recombio S.L Seattle Genetics, Inc. Sorrento Therapeutics, Inc. Spectrum Pharmaceuticals, Inc. Starpharma Holdings Limited Sumitomo Dainippon Pharma Co., Ltd. Syndax Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. Theracrine, Inc. Transgene Biotek Limited Vaxil Bio Therapeutics Ltd. Vertex Pharmaceuticals Incorporated Wilex AG WntResearch AB ZIOPHARM Oncology, Inc. Zymeworks Inc. Zyngenia, Inc.To view the table of contents and know more details please visit Metastatic Breast Cancer - Pipeline Review, H2 2014